Assembly Biosciences is advancing its herpes drug to Phase II trials after it showed 94% antiviral efficacy in a Phase Ib ...

Assembly Biosciences, Inc.'s ABI-5366 showed strong interim phase 1b results in HSV-2 recurrent genital herpes patients.

Growing research shows common herpes viruses may raise dementia risk, challenging previous skepticism and opening new paths ...

Assembly Biosciences ( NASDAQ: ASMB) reported promising results from an early stage study of its experimental candidate, ...

DELRAY BEACH, FL / ACCESS Newswire / August 12, 2025 / Adolore BioTherapeutics, Inc., (“Company” or “Adolore”) announced that ...

Many young adults make the choice to hook up and have sex in college, but they’re not always educated about how to prevent ...

A 56-year-old woman with a history of relapsed/refractory IgG kappa multiple myeloma presented with a 3-day history of right ...

A striking breakthrough in cancer therapy has emerged from an unexpected source: the common herpes simplex virus. A new ...

Raipur: The state viral research and diagnostic laboratory (VRDL) at the All India Institute of Medical Sciences (AIIMS), ...

On track for proof-of-concept Phase 1b data no later than this fall in participants with recurrent genital herpes for long-acting herpes simplex virus (HSV) helicase-primase inhibitor candidates, ...